A prospective, non-randomised phase II study of trastuzumab and capecitabine in patients with HER2 expressing advanced pancreatic cancer

Trial Profile

A prospective, non-randomised phase II study of trastuzumab and capecitabine in patients with HER2 expressing advanced pancreatic cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2010

At a glance

  • Drugs Capecitabine; Trastuzumab
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 28 Jun 2010 Status changed from completed to discontinued according to information reported at ASCO 2010.
    • 08 Jun 2010 Study information reported at ASCO 2010.
    • 20 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top